Latest Patents News

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.

Aquirian Limited has bolstered its growth trajectory with a $20 million Mt Ida contract and significant advancements in its patented Collar Keeper® system, alongside commissioning its Wubin facility.

AML3D has landed a nearly $10 million order for four ARCEMY X 6700 systems from Newport News Shipbuilding, expanding its footprint in the US defence manufacturing sector.

EcoGraf Limited has signed a non-binding MoU with Taiwan’s Long Time Technology to develop HFfree® purification facilities and expand battery anode operations across South East Asia and Taiwan, aiming to tap into Tier-1 OEM supply chains.

Calix Limited has successfully completed the first milestone of its ARENA grant for the Zesty Green Iron Demonstration Project, unlocking a $2 million payment and marking a key step forward in its industrial decarbonisation efforts.

Aquirian Limited advances its Drillforce subsidiary with new technology and equipment while mutually ending a planned joint venture with Topgroup, who remains a strategic shareholder.

EVE Health Group has raised $0.9 million to advance its pharmaceutical reformulation programs targeting global markets worth over US$30 billion. The funding will support development of improved delivery technologies for medicines nearing patent expiry.

Titomic Limited is planning to redomicile from Australia to the United States, aiming to deepen its footprint in the US defense and aerospace sectors and pursue a US stock exchange listing.

American Tungsten & Antimony Ltd has reported a significant high-grade antimony discovery from its maiden drilling at the Antimony Canyon Project in Utah, confirming a large-scale mineralised system with promising grades and thicknesses.

Dimerix Limited has completed dosing of the last adult patient in its ACTION3 Phase 3 trial for DMX-200, exceeding its recruitment target and setting the stage for key regulatory milestones.

Orica reports solid first-half earnings growth led by digital and specialty chemicals, while launching a $100 million cost reduction program to navigate supply disruptions and litigation headwinds.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.